TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00957801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 10 mg. administered topically daily for seven days
Study: NCT01890330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Canola Oil Mixture 25 g/d
Description: Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
Study: NCT04664829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Administered orally once a day. Starting dosage: 200mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally twice a day. Dosage: 1000mg/m\^2
Study: NCT01771861

Intervention type: OTHER
Intervention: Trauma team activation
Description: When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
Study: NCT02340078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF II plus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA IDF II
Study: NCT03883971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: Same as previously reported in arm descriptions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nothing other than the ultrasound
Study: NCT01335152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Breast Cancer web-based workbook
Description: 10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
Study: NCT01289938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg oral once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg i.v. metoclopramide once
Study: NCT03541213

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myocardial biopsy
Description: Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myocardial biopsy
Description: Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myocardial biopsy
Description: Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sternal bone marrow biopsy
Description: Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sternal bone marrow biopsy
Description: Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
Study: NCT00957801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medrol
Description: Medrol 6 day dose pack with an additional 4mg dose on day 7
Study: NCT03541213

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sternal bone marrow biopsy
Description: Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
Study: NCT00457665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelfinavir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Study: NCT00961051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational MPS
Description: Multi-purpose solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free
Description: Multi-purpose solution
Study: NCT04292171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Preoperative treatment with Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Preoperative treatment with Placebo
Study: NCT00096486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT02625207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 1)
Description: 300 mg twice daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 1)
Description: 300 mg twice daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 1)
Description: 300 mg twice daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 1)
Description: 300 mg twice daily x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 2)
Description: 150 mg once daily x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (Part 2)
Description: 150 mg once daily x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat (Part 2)
Description: 800/150 mg once daily x 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat (Part 2)
Description: 800/150 mg once daily x 10 days
Study: NCT03275779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Frequency Condition
Description: Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Frequency Condition
Description: Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
Study: NCT00362856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: larazotide acetate
Description: capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: larazotide acetate
Description: capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: larazotide acetate
Description: capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: larazotide acetate
Description: capsule

Intervention type: DRUG
Group type: OTHER
Intervention: larazotide acetate
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT02270905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCELL® Meniscus
Description: decellularised porcine xenograft
Study: NCT00512356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Adhesion Product
Description: Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
Study: NCT03359928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boxing
Description: as already discussed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair stepping
Description: as already discussed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stair climbing
Description: as already discussed
Study: NCT03382210

Intervention type: OTHER
Intervention: Enhanced recovery protocol
Description: Standardized enhanced recovery protocol including 21 perioperative items.
Study: NCT03262233

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT05530642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Resilience Skills Training (ERST)
Description: The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of PSP trainers from each of the PSP pilot sectors (i.e., CanOps, Regina Fire \& Protective Services, Regina Police Service, Saskatoon Police Service, Regina Emergency Medical Services, Ottawa Emergency Medical Services) during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs.
Study: NCT01210742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc One
Description: Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine management
Description: Routine non-operative management for knee OA (NICE guidelines)
Study: NCT00524875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bevacizumab
Description: One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
Study: NCT01201356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg/day
Study: NCT04401787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior resection for upper rectal cancer in obese
Description: Anterior resection for upper rectal cancer in obese

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior resection for upper rectal cancer in obese
Description: Anterior resection for upper rectal cancer in obese
Study: NCT00217971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00934037

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 320 Volume Detector Computed Tomography
Description: Single Arm Study. All patients undergo Volume (Multidetector) CT.

Intervention type: OTHER
Group type: OTHER
Intervention: Other: Multidetector Computed Tomography - 320 detectors
Description: Multidetector computed tomography angiography
Study: NCT04612205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR followed by pelvic floor exercises
Description: The signal generator was an INDIBA® 448 kHz RF device (vagina/rectum) (INDIBA SA, Barcelona, Spain).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor exercises
Description: The patients will instructed to contract their pelvic floor muscles without contracting adjacent muscles, such as the abdomen, glutei and hip adductors muscles twenty repletion consisted of contraction and squeezing of the muscle ten seconds followed by relaxation for twenty second then rested for two minutes. The exercises program lasted for lasting 45 min. divided into 5 min. warming up, 35 min. actual treatment and 5 min. cooling down, three times a week for eight consecutive weeks. The patient will teach to contract their pelvic floor muscles before coughing or sneezing thus to prevent leakage. Home exercises through continuing practicing these contractions as frequent as possible according to her ability, at early morning before getting from bed from crock lying position, at afternoon from sitting and standing positions, at evening from sitting and standing positions and finally at night at bed time from crock lying position.
Study: NCT02841540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-8800 (RVT-2001)
Description: H3B-8800 (RVT-2001) orally at specified doses and schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-8800 (RVT-2001)
Description: H3B-8800 (RVT-2001) orally at specified doses and schedules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-8800 (RVT-2001)
Description: H3B-8800 (RVT-2001) orally at specified doses and schedules.
Study: NCT02280642

Intervention type: BIOLOGICAL
Intervention: Both 2nd and 3rd doses on time

Intervention type: BIOLOGICAL
Intervention: 2nd dose late and 3rd dose on time
Study: NCT00475488

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting
Description: Surgery performed due to coronary artery disease.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting
Description: Surgery performed due to coronary artery disease.
Study: NCT02779010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand washing with soap and Health education
Description: Health education on key environmental variables and hand washing with soap
Study: NCT02280642

Intervention type: BIOLOGICAL
Intervention: 2nd dose on time and 3rd dose late

Intervention type: BIOLOGICAL
Intervention: Both doses late
Study: NCT04591769

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Different tracheal tube cuff design
Description: Comparison of effect between 2 different designs of tracheal tube cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Different tracheal tube cuff design
Description: Comparison of effect between 2 different designs of tracheal tube cuff
Study: NCT03745027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: in vitro fertilization
Description: All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
Study: NCT00755508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and gabapentin
Description: Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and gabapentin
Description: Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
Study: NCT00201734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Levels 1-5: AUC of 6 every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
Study: NCT04369079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual myofascial techniques
Description: Fascial techniques were used together with the following techniques: deep massage of neck and shoulder girdle muscles; trigger point therapy; tissue scar treatment in the vicinity of the scar and directly on the scar, by stretching, breaking, pulling, as well as static and dynamic rolling; post-isometric relaxation (stretching) of shoulder and neck muscles; active release technique of the chest and shoulder; selected fascial distortion model techniques; and fascial manipulation techniques consisting of developing specific CC-center of coordination and CF-center of fusion points in the operated area and the shoulder on the same side.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy consisting of exercise and massage.
Description: Underwent kinesiotherapeutic procedures that included various floor gymnastic exercises with gymnastic stick, balls, and/or elastic tapes, conventional massage of neck and shoulder girdle muscles and therapeutic exercises to increase ROM in the upper limb and in the chest area.
Study: NCT05041244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy delivered through VAC
Description: Initial cycle: Continuous first 48 hours Subsequent cycle: Consider intermittent DPC (5 min ON/2 mins OFF) for rest of the therapy Target Target Pressure: 50-175mmHg, to be titrated for more drainage Dressing change interval: every week; need for more frequent dressing need to be evaluated. More frequent change of adaptic can be considered. (Adaptic is a layer of thin dressing that will be in direct contact with the wound to reduce the risk of maceration and adherence to the dressing)

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of care
Description: Participants in the control arm will have their dressings changed as per the current standard of care.~Effective management of DFU will depend on accurate diagnosis and assessment and appropriate debridement of non-viable tissues in patients from both arms Patients will be advised to continue off loading and any evidence of early infection should be promptly treated.
Study: NCT00503932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
Study: NCT00280501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine (drug)
Description: Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine (drug)
Description: Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine (drug)
Description: Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride (drug)
Description: Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride (drug)
Description: Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulpiride (drug)
Description: Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02464527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus-stimulus pairing
Description: The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimulus-stimulus pairing
Description: The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocal recorder
Description: The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocal recorder
Description: The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
Study: NCT02164539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
Study: NCT00506415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 5 cm^2
Description: 5 cm\^2 transdermal patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine 10 cm^2
Description: 10 cm\^2 transdermal patch.